This report presents a strategic analysis of the UAE Cardiac Monitoring Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the UAE Cardiac Monitoring Devices Market, offering unmatched value, accuracy, and expert insights.
The UAE Cholesterol Therapeutics Market is anticipated to experience a growth from $122 Mn in 2022 to $161 Mn by 2030, with a CAGR of 3.6% during the forecast period of 2022-2030. The key factors propelling the market growth in the UAE include the rising prevalence of dyslipidemia due to factors like urbanization, western dietary patterns, and obesity, increased awareness about the health risks associated with high cholesterol, and significant government investments and initiatives aimed at improving healthcare facilities. The UAE Cholesterol Therapeutics Market encompasses various players across different segments, Amgen, Pfizer, Merck, AstraZeneca, Johnson & Johnson, Julphar, Cadila, Sinopharm, Sanofi, AbbVie, etc., among various others.
This report presents a strategic analysis of the UAE Women Health Diagnostic Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UAE Women Health Diagnostic Market, offering unmatched value, accuracy and expert insights.
This report presents a strategic analysis of the UAE Patient Support Programs (PSP) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UAE Patient Support Programs (PSP) Market, offering unmatched value, accuracy and expert insights.
This report presents a strategic analysis of the UAE Medical and Diagnostic Laboratory Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UAE Medical and Diagnostic Laboratory Service Market, offering unmatched value, accuracy and expert insights.
This report presents a strategic analysis of the UAE In Vitro Fertilisation (IVF) Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UAE In Vitro Fertilisation (IVF) Service Market, offering unmatched value, accuracy and expert insights.
This report presents a strategic analysis of the UAE Healthcare Reimbursement Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UAE Healthcare Reimbursement Market, offering unmatched value, accuracy and expert insights.
This report presents a strategic analysis of the UAE Healthcare Diagnostics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UAE Healthcare Diagnostics Market, offering unmatched value, accuracy and expert insights.
The UAE physiotherapy market size was valued at $266 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.85% from 2022 to 2030 and will reach $452 Mn in 2030. UAE physiotherapy market is expected to grow due to an increase in the number of people suffering from chronic conditions such as obesity and diabetes. The market is segmented by Product Type, Application Type, and End User. The major layers in the UAE physiotherapy market Medstar Medical Equipment, Gulf Medical Equipment, Euro Med, Mediplus and others.
The UAE home healthcare market was valued at $1.83 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.93% from 2022 to 2030 and will reach $3.59 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, many insurances now include home healthcare. The market is segmented by equipment outlook and by services. Some key players in this market are Omega Home Health Care, Ishraq home healthcare, bayti Home Healthcare, Manzil, Mediclinic, NMC Health, and Alleanza.
UAE Antibacterial (Antibiotics) Drugs Market is at around $0.25 Bn in 2023 and is projected to reach $0.3 Bn in 2030, exhibiting a CAGR of 5.2% during the forecast period. The market is being driven by the increasing prevalence of infectious diseases, government healthcare initiatives, and growing population and urbanization. The market is dominated by key players like Julphar Gulf Pharmaceutical Industries, Tabuk Pharmaceuticals, Pfizer, AstraZeneca plc, GlaxoSmithKline (GSK), Johnson & Johnson Inc. (J&J), Merck & Co., Sanofi, Novartis, and F. Hoffmann-La Roche Ltd.
This report presents a strategic analysis of the UAE Pain Management Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the UAE Pain Management Devices Market, offering unmatched value, accuracy and expert insights.
The UAE healthcare insurance market is projected to grow from $10.131 Bn in 2022 to $19.6 Bn by 2030, registering a CAGR of 8.6% during the forecast period of 2022-2030. The main factors driving the growth would be the increasing population, rising healthcare costs, technological advancements and government support. The market is segmented by the component, provider, coverage, health insurance plans and end-user. Some of the major players include Dubai Islamic Insurance & Reinsurance, MetLife, Abu Dhabi National Insurance, Orient Health, Adamjee, Oman Insurance Company, Ras Al Khaimah National Insurance, Daman, Emirates Insurance and AXA Gulf.
The UAE dental care market size is at around $179 Mn in 2022 and is projected to reach $318 Mn in 2030, exhibiting a CAGR of 7.4% during the forecast period from 2022 to 2030. The market is growing as the new medical tourism destination for dental care services and is dominated by players like American Dental Clinic, Dr. Sulaiman Al Habib Medical Group, Aster DM Healthcare, and Medcare Hospitals & Medical Centers.
The UAE Retail Pharmacy Market is projected to grow from $5.193 Bn in 2022 to $9.541 Bn by 2030, registering a CAGR of 7.9% during the forecast period of 2022-2030. The market is expected to continue growing at a steady pace in the coming years, with an increasing number of retail pharmacy chains and independent pharmacies opening in the country. Lloyds Pharmacy is a leading retail pharmacy chain in the UAE, with over 70 branches across the country.
This report presents a strategic analysis of the UAE Blockchain Technology in the Healthcare Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the UAE Blockchain Technology in the Healthcare Market, offering unmatched value, accuracy, and expert insights.
UAE alzheimer’s therapeutics market valued at $24 Mn in 2022, projected to reach $52 Mn by 2030 with a 10.1% CAGR. As the population ages, the prevalence of Alzheimer's disease rises, driving demand for Alzheimer's treatment drugs, one of the major factors driving the market's growth. Leading pharmaceutical companies that are currently working in the market are Pfizer, Eisai, Janssen, Biogen, Roche, Novartis, Lundbeck, Otsuka Pharmaceutical, Teva Pharmaceutical and Sun Pharmaceutical.
UAE Infectious Disease Drugs Market valued at $0.59 Bn in 2023, projected to reach $0.85 Bn by 2030 with a 5.27% CAGR. The market is being driven by the prevalence of infectious diseases, government initiatives, and rising healthcare expenditure. The market is dominated by key players like Hikma Pharmaceuticals, Julphar Gulf Pharmaceutical Industries, Neopharma, AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, and Janssen Pharmaceuticals.
The UAE Atopic Dermatitis Therapeutics Market was valued at US $62 Mn in 2022, and is predicted to grow at (CAGR) of 9.8% from 2023 to 2030, to US $130 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies, and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, and Merck, among others.
UAE Atherosclerosis Therapeutics Market was valued at $14 Mn in 2022 and is estimated to reach $24 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the growing incidence of cardiovascular diseases, which are being exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The leading pharmaceutical companies presently operating in the market are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Johnson & Johnson, Teva Pharmaceutical, Roche and Merck & Co.
The UAE Asthma and COPD Therapeutics Market was valued at US $167 Mn in 2022, and is predicted to grow at (CAGR) of 6.20% from 2023 to 2030, to US $270 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, supportive government initiatives, unmet demand, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Teva, Merck Novartis, AstraZeneca, Pfizer, and Boehringer Ingelheim, among others.
UAE HIV Drugs Market is at around $0.16 Bn in 2023 and is projected to reach $0.22 Bn in 2030, exhibiting a CAGR of 4.6% during the forecast period. Factors including improvements in drug development, rising healthcare costs, and migration and tourism are driving the market. The market is dominated by key players like Julphar, Neopharma, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.
UAE Antifungal Drugs Market is at around $0.07 Bn in 2023 and is projected to reach $0.1 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period. The market is expanding due to factors such as the prevalence of fungal infections, improvements in healthcare infrastructure, and technological advancements in drug development. The market is dominated by key players like Neopharma, Abbott Laboratories, Merck & Co., Inc., Astellas Pharma Inc., Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
UAE alopecia drugs (hair loss) market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of alopecia, rising awareness and consciousness among individuals about their appearance, and the development of advanced treatment technologies. Johnson & Johnson, Merck & Co., GlaxoSmithKline plc, Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Histogen Inc., Aclaris Therapeutics, and Concert Pharmaceuticals are the key players in this market.
UAE Aminoglycosides Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The Aminoglycosides market is a segment of the pharmaceutical industry that focuses on the production and sale of aminoglycoside antibiotics. Key factors driving the market include the increasing prevalence of bacterial infections, especially drug-resistant strains, which require potent antibiotics like aminoglycosides. The growing geriatric population and the rise in chronic diseases also contribute to the demand for aminoglycosides. The market analysis also considers restraints such as the potential side effects and toxicity associated with aminoglycoside use. These antibiotics can cause serious adverse effects, including kidney damage and hearing loss, which limit their long-term use. Furthermore, the emergence of alternative antibiotics and the growing concern over antibiotic resistance pose challenges to the market growth. Some of the prominent global players in the Aminoglycosides market include Pfizer Inc., Merck & Co., Inc., Novartis AG, Bristol Myers Squibb Company, Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.